Science Nominees Wait For OK to Begin Work

WASHINGTON—Almost five months after President Reagan announced the intention to nominate him, plasma physicist Robert Hunter waits in San Diego for word of his confirmation hearing to become director of the Office of Energy Research at the Department of Energy. The office, overseen since April by acting director James Decker after the departure of Alvin Trivelpiece, is the focal point for several of the hottest issues on the nation’s science agenda, including the Superconducting

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—Almost five months after President Reagan announced the intention to nominate him, plasma physicist Robert Hunter waits in San Diego for word of his confirmation hearing to become director of the Office of Energy Research at the Department of Energy.

The office, overseen since April by acting director James Decker after the departure of Alvin Trivelpiece, is the focal point for several of the hottest issues on the nation’s science agenda, including the Superconducting Supercollider, the proposal to sequence the human genome, and the role of the national laboratories in commercializing basic research. But Hunter is 3,000 miles away running a company, Western Research Corporation, that explores laser technologies.

“I’m trying to educate myself by reading documents and reports, but I don’t have access to anything that isn’t public,” said Hunter. “I am not involved officially in any departmental business.”

The subcommittee of the Senate Energy and National Resources Committee ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies